A Randomized multicenter phase III study of single-administration of mecapegfilgrastim (HHPG-19K), a pegfilgrastim biosimilar, for prophylaxis of chemotherapy-induced neutropenia in patients with advanced non-small cell lung cancer (NSCLC)

The efficacy and safety profile of mecapegfilgrastim as prophylactic use among NSCLC patients in this two-stage study. From the double-blind stage and open label stage, not only the efficacy comparing mecapegfilgrastim and short action G-CSF was explored, but also the exact incidence of neutropenia and FN in this population was well studied.

from #ORL-AlexandrosSfakianakis via simeraentaxei on Inoreader http://ift.tt/1k3SAcV
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1QO1gRz
via IFTTT